[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100427553":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":33,"responsibleParty":70,"collaborators":73,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":52,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":52,"maxAge":52,"enrollmentInfo":86,"targetDuration":52,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":36,"whyStopped":52,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Neuroendocrine cancer patients","EXPERIMENTAL","All neuroendocrine cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with 3 MBq\u002Fkg (maximum 370 MBq) of 68Ga-DOTA-TATE. 45-90 minutes following injection, patients will be imaged in a PET\u002FCT scanner. Images will be analyzed by a trained nuclear medicine physician.\n\nSafety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed.",[13],"Diagnostic Test: 68Ga-DOTA-TATE",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","68Ga-DOTA-TATE","The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET\u002FCT image acquisition.",[9],[21],"Netspot",[23],{"name":24,"affiliation":5,"role":25},"Éric E Turcotte, MD","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Stéphanie Dubreuil","CONTACT","819-346-1110","16617","Stephanie.Dubreuil2@usherbrooke.ca",[34,56],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Centre Intégré Universitaire de Santé et des Services Sociaux du Centre de l'Ouest de Montréal - Jewish General Hospital","RECRUITING","Montreal","Quebec","H3T 1E2","Canada","CA",{"type":43,"coordinates":44},"Point",[45,46],-73.58781,45.50884,{"lat":46,"lon":45},[49,54],{"name":50,"role":29,"phone":51,"phoneExt":52,"email":53},"Gad Abikhzer, MD","514-340-8222",null,"gad101@hotmail.com",{"name":50,"role":55,"phone":52,"phoneExt":52,"email":52},"SUB_INVESTIGATOR",{"facility":57,"status":36,"city":58,"state":38,"zip":59,"country":40,"countryCode":41,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"CHUS","Sherbrooke","J1H 5N4",{"type":43,"coordinates":61},[62,63],-71.89908,45.40008,{"lat":63,"lon":62},[66,68],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":67},"Stephanie.Dubreuil2@Usherbrooke.ca",{"name":69,"role":25,"phone":52,"phoneExt":52,"email":52},"Éric Turcotte, MD",{"type":25,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":52,"oldOrganization":52},"Dr Éric E Turcotte, MD","Head of the clinical research, CIMS, CHUS",[74,76],{"name":75,"class":6},"Université de Sherbrooke",{"name":77,"class":6},"Jewish General Hospital","100427553","phase-3-68ga-dota-tate-petct-imaging-in-nets-100427553",false,"NCT04847505","68Ga-DOTA-TATE PET\u002FCT Imaging in NETs","Pragmatic Study on the Use of 68Ga-DOTA-TATE PET|CT Imaging as a Standard of Care to Influence Clinical Management","Inclusion Criteria:\n\n1. Clinical requisition for a 68Ga-DOTA-TATE PET\u002FCT signed by a referring doctor\n2. Patients with suspected or proven tumors expressing somatostatin receptors\n3. Informed consent by patient (or parents if patient is less than 18 years of age)\n\nExclusion Criteria:\n\n1. \\*Pregnancy (not an absolute exclusion). See below\\*.\n2. Patient refusal to participate.\n3. Prior severe anaphylactic reaction to DOTA-TATE or somatostatin analogs.\n\n   * In the case of a diagnostic procedure in a patient who is or may be pregnant, the principle of benefits-disadvantages would be applied following an in-depth discussion with the treating physicians and the patient. In this context, any clinical situation in which the patient's life would be at stake by excluding her from the study would be considered. The conditions to decide whether to include the patient would be:\n\n     * Severe medical condition involving the life of the pregnant woman and\u002For the fetus;\n     * Existing treatments that are ineffective or may present toxicity to the woman and\u002For fetus;\n     * High clinical suspicion of a somatostatin receptor overexpressing tumour;\n     * Negative, indeterminate or contraindicated first-line imaging tests;\n     * Therapeutic gesture considered during pregnancy based on the results of the examination, which may include termination of pregnancy or premature delivery;\n     * Documented discussion with the treating team and the patient;\n     * Patient agrees.","ALL",{"count":87,"type":88},5000,"ESTIMATED","INTERVENTIONAL",[91],"PHASE3","This clinical trial is a pragmatic study aiming to evaluate the innocuity\u002Fsafety profile of the PET radiotracer 68Ga-DOTA-TATE, and to establish the procedure as a routine standard-of-care diagnostic tool for all neuro-endocrine cancer patients. It is a single-center study, but with recruitment across all Canada. The trial is prospective, non-randomized, open-label and with no control group. The superiority of this procedure over the former standard-of-care (Octreoscan) was already established in previous and numerous studies across the world. As such, the current trial aims to gather data to further support the implementation of 68Ga-DOTA-TATE as the new standard-of-care for neuro-endocrine tumors (NET).",[94],"Neuroendocrine Tumors",[17,96,97,98],"PET imaging","Pragmatic study","Neuroendocrine tumors (NET)","2024-07-16",{"date":101,"type":102},"2024-07-18","ACTUAL",{"date":104,"type":102},"2020-01-01",{"date":106,"type":88},"2025-12-31",{"name":5,"class":6},2]